GH-2616

N/A

Report date: 2024/02/02 15:22:04
NME

Base Information

Drug NameGH-2616
Drug Alias NameGH-2616GH2626GH-2626
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKinesin-like protein KIF18A inhibitors
TargetsKinesin-like protein KIF18A
Therapy Area/IndicationsBrain metastasesSolid tumoursBrain Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Genhouse Bio Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQinhao Pharmaceutical (Suzhou) Co., Ltd. Beijing BranchSuzhou Genhouse Bio Co Ltd
Inactive CompaniesN/A
Active IndicationsBrain metastasesSolid tumoursBrain Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A